Overview

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Status:
Terminated
Trial end date:
2019-02-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and 2006-66.
Phase:
Phase 2
Details
Lead Sponsor:
University of Arkansas
Collaborators:
Amgen
Onyx Pharmaceuticals
Treatments:
BB 1101
Cisplatin
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Etoposide
Etoposide phosphate
Lenalidomide
Lenograstim
Liposomal doxorubicin
Melphalan
Thalidomide